SCHEMBL1066697

SCHEMBL1066697

COC(=O)c1ccc(-c2ccc([N+](=O)[O-])c(NC(=O)c3ccc(OC)cc3)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 6/20 0.60
ABCC1 P33527 3/20 0.58
MAPT P10636 5/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
MAPK1 P28482 1/20 0.56
ALDH1A1 P00352 4/20 0.55
KDM4E B2RXH2 3/20 0.55
HPGD P15428 3/20 0.55
HDAC2 Q92769 1/20 0.53
LMNA P02545 3/20 0.52
MAPK10 P53779 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
F10 P00742 2/20 0.50
POLB P06746 1/20 0.50
GAA P10253 1/20 0.49
KMT2A Q03164 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4581161 0.88 ABCB1 (0.57) ABCB1ABCC1MAPTSMN1; SMN2NPC1
SCHEMBL4314789 0.83 ABCB1 (0.55) ABCB1ABCC1MAPTSMN1; SMN2NPC1
SCHEMBL8293254 0.82 MAPT (0.59) ABCB1ABCC1MAPTSMN1; SMN2NPC1
SCHEMBL4579515 0.81 ABCB1 (0.55) ABCB1ABCC1MAPTSMN1; SMN2NPC1
SCHEMBL1065793 0.81 HDAC2 (0.79) MAPTMAPK1ALDH1A1KDM4EHPGD
SCHEMBL1067097 0.80 MAPT (0.49) ABCB1ABCC1MAPTSMN1; SMN2NPC1
SCHEMBL1067526 0.80 MAPT (0.49) ABCB1ABCC1MAPTSMN1; SMN2NPC1
SCHEMBL30061157 0.80 ABCB1 (0.53) ABCB1ABCC1MAPTSMN1; SMN2NPC1
SCHEMBL4580292 0.79 MAPT (0.48) ABCB1ABCC1MAPTSMN1; SMN2NPC1
SCHEMBL4580126 0.79 MAPT (0.48) ABCB1ABCC1MAPTSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868205-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
US-20080132459-A1 Inhibitors of Histone Deacetylase METHYLGENE, INC. (CA) 2008-06-05 US disclosed
EP-1663953-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2006-06-07 EP disclosed
WO-2005030705-A9 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2006-04-20 WO disclosed
WO-2005030705-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2005-04-07 WO disclosed
WO-2005030704-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2005-04-07 WO disclosed
WO-2005030704-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132459-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 ABCB1 4043/4885ABCC1 3326/4885MAPT 2110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.